{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:55:08Z","timestamp":1792652108553,"version":"4.5.0"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81300409"],"award-info":[{"award-number":["81300409"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bbrc.2023.09.023","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:39:04Z","timestamp":1694738344000},"page":"61-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["HDAC inhibitors: Promising agents for leukemia treatment"],"prefix":"10.1016","volume":"680","author":[{"given":"Yun","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2023.09.023_bib1","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.drudis.2021.05.009","article-title":"Recent progress on targeting leukemia stem cells","volume":"26","author":"Ma","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbrc.2023.09.023_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-017-0543-7","article-title":"Precision therapy for acute myeloid leukemia","volume":"11","author":"Yang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.semcancer.2017.09.001","article-title":"Epigenetics in pediatric acute lymphoblastic leukemia","volume":"51","author":"Nordlund","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","article-title":"Molecular biomarkers in acute myeloid leukemia","volume":"31","author":"Prada-Arismendy","year":"2017","journal-title":"Blood Rev."},{"key":"10.1016\/j.bbrc.2023.09.023_bib5","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.biopha.2018.07.133","article-title":"Epigenetics and Epi-miRNAs: potential markers\/therapeutics in leukemia","volume":"106","author":"Memari","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2023.09.023_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2023.09.023_bib7","article-title":"HDAC inhibitors in acute myeloid leukemia","volume":"11","author":"San","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2023.09.023_bib8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2141.2009.07887.x","article-title":"Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors","volume":"147","author":"Gloghini","year":"2009","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.bbrc.2023.09.023_bib9","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100889","article-title":"T time: emerging and new therapies for peripheral T-cell lymphoma","volume":"52","author":"Mina","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.bbrc.2023.09.023_bib11","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/phar.1671","article-title":"Role of histone deacetylase inhibitors in relapsed refractory multiple myeloma: a focus on vorinostat and panobinostat","volume":"35","author":"Afifi","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbrc.2023.09.023_bib12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s13238-020-00694-x","article-title":"HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma","volume":"11","author":"Wang","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.bbrc.2023.09.023_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","article-title":"HDAC and HDAC inhibitor: from cancer to cardiovascular diseases","volume":"52","author":"Yoon","year":"2016","journal-title":"Chonnam Med J"},{"key":"10.1016\/j.bbrc.2023.09.023_bib14","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2023.09.023_bib15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2023.09.023_bib16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.sbi.2005.10.006","article-title":"Structure and activity of enzymes that remove histone modifications","volume":"15","author":"Holbert","year":"2005","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2023.09.023_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2023.09.023_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2023.09.023_bib20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2009.06.049","article-title":"Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2023.09.023_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/hepr.12757","article-title":"Histone deacetylases function as novel potential therapeutic targets for cancer","volume":"47","author":"Zhang","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/fon.11.2","article-title":"Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer","volume":"7","author":"Thurn","year":"2011","journal-title":"Future Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib23","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/cas.13062","article-title":"Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies","volume":"107","author":"Imai","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbrc.2023.09.023_bib24","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3324\/haematol.2013.092643","article-title":"Sin3a-associated Hdac1 and Hdac2 are essential for hematopoietic stem cell homeostasis and contribute differentially to hematopoiesis","volume":"99","author":"Heideman","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2023.09.023_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","article-title":"Histone deacetylases and cancer","volume":"6","author":"Barneda-Zahonero","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbrc.2023.09.023_bib27","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1349-7006.2001.tb02153.x","article-title":"Expression profile of histone deacetylase 1 in gastric cancer tissues","volume":"92","author":"Choi","year":"2001","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pros.20022","article-title":"Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer","volume":"59","author":"Halkidou","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.bbrc.2023.09.023_bib29","doi-asserted-by":"crossref","first-page":"13548","DOI":"10.1074\/jbc.M510023200","article-title":"Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer","volume":"281","author":"Wilson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2023.09.023_bib30","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/ijc.25151","article-title":"Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin","volume":"127","author":"Hayashi","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2023.09.023_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-004-1668-2","article-title":"Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis","volume":"90","author":"Krusche","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbrc.2023.09.023_bib32","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1158\/1078-0432.CCR-04-0455","article-title":"HDAC6 expression is correlated with better survival in breast cancer","volume":"10","author":"Zhang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib33","doi-asserted-by":"crossref","first-page":"37966","DOI":"10.18632\/oncotarget.9274","article-title":"HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2023.09.023_bib34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2141.2010.08301.x","article-title":"Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia","volume":"150","author":"Moreno","year":"2010","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.bbrc.2023.09.023_bib35","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/med.21437","article-title":"The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat","volume":"37","author":"Zagni","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bbrc.2023.09.023_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2023.09.023_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3807","article-title":"Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine","volume":"31","author":"Suresh","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.bbrc.2023.09.023_bib38","doi-asserted-by":"crossref","first-page":"616","DOI":"10.21147\/j.issn.1000-9604.2021.05.08","article-title":"Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma","volume":"33","author":"Gui","year":"2021","journal-title":"Chinese J Cancer Res"},{"key":"10.1016\/j.bbrc.2023.09.023_bib39","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2023.09.023_bib40","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2023.09.023_bib41","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2174\/092986705774454706","article-title":"Non-hydroxamate histone deacetylase inhibitors","volume":"12","author":"Suzuki","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbrc.2023.09.023_bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J. Antibiot."},{"key":"10.1016\/j.bbrc.2023.09.023_bib43","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/neuonc\/noaa249","article-title":"Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naive diffuse midline glioma models","volume":"23","author":"Vitanza","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib44","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-08-1215","article-title":"Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma","volume":"15","author":"Woo","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib45","article-title":"Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin","volume":"164","author":"El","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2023.09.023_bib46","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib47","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/pgs-2016-0113","article-title":"Pharmacogenomics and histone deacetylase inhibitors","volume":"17","author":"Goey","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bbrc.2023.09.023_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.phrs.2016.01.002","article-title":"UGT genotyping in belinostat dosing","volume":"105","author":"Goey","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib49","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Brit J Clin Pharmaco"},{"key":"10.1016\/j.bbrc.2023.09.023_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib51","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","article-title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Jiang","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib52","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/17460441.2015.1038236","article-title":"Emerging approaches for histone deacetylase inhibitor drug discovery","volume":"10","author":"Zwergel","year":"2015","journal-title":"Expert Opin Drug Dis"},{"key":"10.1016\/j.bbrc.2023.09.023_bib53","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/cas.12965","article-title":"Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells","volume":"107","author":"Matsuda","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbrc.2023.09.023_bib54","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2013.815165","article-title":"Panobinostat in lymphoid and myeloid malignancies","volume":"22","author":"Khot","year":"2013","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrc.2023.09.023_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21111608","article-title":"Natural compound histone deacetylase inhibitors (HDACi): synergy with inflammatory signaling pathway modulators and clinical applications in cancer","volume":"21","author":"Losson","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2023.09.023_bib56","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4155\/fmc.12.80","article-title":"Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives","volume":"4","author":"Giannini","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bbrc.2023.09.023_bib57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.blre.2016.02.001","article-title":"Update on rational targeted therapy in AML","volume":"30","author":"Shafer","year":"2016","journal-title":"Blood Rev."},{"key":"10.1016\/j.bbrc.2023.09.023_bib58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.bbrc.2023.09.023_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cytogfr.2018.08.004","article-title":"The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators","volume":"43","author":"Binder","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbrc.2023.09.023_bib60","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bbrc.2023.09.023_bib61","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.leukres.2010.11.006","article-title":"Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival","volume":"35","author":"Tickenbrock","year":"2011","journal-title":"Leukemia Res"},{"key":"10.1016\/j.bbrc.2023.09.023_bib62","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fcell.2020.00844","article-title":"HDAC8: a promising therapeutic target for acute myeloid leukemia","volume":"8","author":"Spreafico","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041039","article-title":"The class IIA histone deacetylase (HDAC) inhibitor TMP269 downregulates ribosomal proteins and has anti-proliferative and pro-apoptotic effects on AML cells","volume":"15","author":"Urwanisch","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2023.09.023_bib64","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1128\/MCB.21.19.6470-6483.2001","article-title":"ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain","volume":"21","author":"Amann","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib65","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1038\/sj.onc.1204593","article-title":"AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML","volume":"20","author":"Licht","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2023.09.023_bib66","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2006.03.012","article-title":"The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1\/ETO's activity","volume":"9","author":"Liu","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2023.09.023_bib67","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1038\/sj.onc.1207727","article-title":"The 8;21 translocation in leukemogenesis","volume":"23","author":"Peterson","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2023.09.023_bib68","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1124\/jpet.106.118406","article-title":"Targeting AML1\/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1\/ETO-positive acute myeloid leukemia cells","volume":"321","author":"Liu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbrc.2023.09.023_bib69","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.onc.1209760","article-title":"Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein","volume":"26","author":"Yang","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2023.09.023_bib70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nm1160","article-title":"Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway","volume":"11","author":"Insinga","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2023.09.023_bib71","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1158\/2159-8290.CD-20-1145","article-title":"Epigenetic activation of plasmacytoid DCs drives IFNAR-dependent therapeutic differentiation of AML","volume":"12","author":"Salmon","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2023.09.023_bib72","doi-asserted-by":"crossref","first-page":"11001","DOI":"10.1007\/s13277-016-4985-2","article-title":"Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia","volume":"37","author":"Davood","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.bbrc.2023.09.023_bib73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40164-023-00383-5","article-title":"Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2\/c-Myc\/RCC1 axis in acute myeloid leukemia","volume":"12","author":"Gu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113398","article-title":"The novel class IIa selective histone deacetylase inhibitor YAK540 is synergistic with bortezomib in leukemia cell lines","volume":"23","author":"Bollmann","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2023.09.023_bib75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00204-021-03174-1","article-title":"Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3","volume":"96","author":"Wachholz","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib76","first-page":"3169","article-title":"Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2\/STAT3 signaling","volume":"8","author":"Zhao","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.bbrc.2023.09.023_bib77","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1038\/bcj.2012.14","article-title":"The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML","volume":"2","author":"Novotny-Diermayr","year":"2012","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbrc.2023.09.023_bib78","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/347558a0","article-title":"The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus","volume":"347","author":"de The","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2023.09.023_bib79","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood-2012-10-461988","article-title":"A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance","volume":"121","author":"Santoro","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.09.023_bib80","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.bbrc.2023.09.023_bib81","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/jnci\/90.21.1621","article-title":"Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase","volume":"90","author":"Warrell","year":"1998","journal-title":"JNCI-J Natl Cancer I"},{"key":"10.1016\/j.bbrc.2023.09.023_bib82","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.1038\/sj.onc.1204853","article-title":"Transcriptional regulation in acute promyelocytic leukemia","volume":"20","author":"Lin","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2023.09.023_bib83","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.3892\/mmr.2017.6290","article-title":"Role of histone deacetylase expression levels and activity in the inflammatory responses of patients with chronic hepatitis B","volume":"15","author":"Zhang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbrc.2023.09.023_bib84","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-19-0171","article-title":"Histone deacetylase inhibition with panobinostat combined with intensive induction chemotherapy in older patients with acute myeloid leukemia: phase I study results","volume":"25","author":"Wieduwilt","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib85","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1200\/JCO.2011.38.3265","article-title":"Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome","volume":"30","author":"Garcia-Manero","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib86","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1080\/10428194.2020.1719095","article-title":"Phase I study of AR-42 and decitabine in acute myeloid leukemia","volume":"61","author":"Liva","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2023.09.023_bib87","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/leu.2017.159","article-title":"A phase 1b\/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u2a7d30% blasts","volume":"31","author":"Garcia-Manero","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2023.09.023_bib88","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/leu.2016.303","article-title":"A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials","volume":"31","author":"Montalban-Bravo","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2023.09.023_bib89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13016","article-title":"A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome","volume":"167","author":"Kirschbaum","year":"2014","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.bbrc.2023.09.023_bib90","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13148-020-00923-4","article-title":"Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed\/refractory acute myeloid leukemia: a single-arm, phase 1\/2 study","volume":"12","author":"Wang","year":"2020","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.bbrc.2023.09.023_bib91","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib92","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bbrc.2023.09.023_bib93","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2141.2002.03955.x","article-title":"Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia","volume":"119","author":"Crazzolara","year":"2002","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.bbrc.2023.09.023_bib94","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/leu.2011.140","article-title":"TAL1\/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells","volume":"25","author":"Cardoso","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2023.09.023_bib95","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3109\/10428194.2012.663085","article-title":"Hyper-activation of WNT\/beta-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia","volume":"53","author":"Shao","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2023.09.023_bib96","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2009.22.0996","article-title":"Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII\/ECOG E2993 protocol","volume":"27","author":"Mansour","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib97","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11684-021-0877-y","article-title":"Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia","volume":"16","author":"Xi","year":"2022","journal-title":"Front Med-Prc"},{"key":"10.1016\/j.bbrc.2023.09.023_bib98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00277-012-1561-8","article-title":"Notch1 signaling is irresponsible to the anti-leukemic effect of HDACis in B-ALL Nalm-6 cells","volume":"92","author":"Shao","year":"2013","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib99","article-title":"The combination of curaxin CBL0137 and histone deacetylase inhibitor panobinostat delays KMT2A-rearranged leukemia progression","volume":"12","author":"Xiao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib100","article-title":"The histone deacetylase inhibitor I1 induces differentiation of acute leukemia cells with MLL gene rearrangements via epigenetic modification","volume":"13","author":"Yao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib101","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/leu.2017.216","article-title":"The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20\/RNF40\/WAC-H2B ubiquitination axis","volume":"32","author":"Garrido","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2023.09.023_bib102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11899-020-00582-5","article-title":"MLL-rearranged acute lymphoblastic leukemia","volume":"15","author":"El","year":"2020","journal-title":"Curr Hematol Malig R"},{"key":"10.1016\/j.bbrc.2023.09.023_bib103","doi-asserted-by":"crossref","first-page":"292","DOI":"10.18632\/genesandcancer.117","article-title":"Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia","volume":"7","author":"Li","year":"2016","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bbrc.2023.09.023_bib104","first-page":"419","article-title":"Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia","volume":"89","author":"Romanski","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2023.09.023_bib105","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1158\/1078-0432.CCR-19-0516","article-title":"Purinostat mesylate is a uniquely potent and selective inhibitor of HDACs for the treatment of BCR-ABL-induced B-cell acute lymphoblastic leukemia","volume":"25","author":"Yang","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib106","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1182\/blood-2007-10-117762","article-title":"The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells","volume":"111","author":"Scuto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.09.023_bib107","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/leu.2012.31","article-title":"Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia","volume":"26","author":"Vilas-Zornoza","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2023.09.023_bib108","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3109\/10428194.2011.577259","article-title":"Inhibition of histone deacetylase 6 as a therapeutic strategy for acute lymphocytic leukemia","volume":"52","author":"Eklund","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2023.09.023_bib109","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3109\/10428194.2011.570821","article-title":"Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells","volume":"52","author":"Aldana-Masangkay","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2023.09.023_bib110","first-page":"779","article-title":"Effects of valproic acid and pioglitazone on cell cycle progression and proliferation of T-cell acute lymphoblastic leukemia Jurkat cells","volume":"19","author":"Jazi","year":"2016","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.bbrc.2023.09.023_bib111","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-015-0176-7","article-title":"The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo","volume":"8","author":"Chao","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib112","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.18632\/oncotarget.2992","article-title":"mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells","volume":"6","author":"Beagle","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2023.09.023_bib113","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/1078-0432.CCR-12-1511","article-title":"Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K\/AKT, and NF-kappaB","volume":"19","author":"Bastian","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106707","article-title":"Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia","volume":"110","author":"Carraway","year":"2021","journal-title":"Leukemia Res"},{"key":"10.1016\/j.bbrc.2023.09.023_bib115","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2012-01-401687","article-title":"Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia","volume":"119","author":"Bhatla","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.09.023_bib116","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ajh.23778","article-title":"A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"89","author":"Burke","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib117","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1158\/1078-0432.CCR-19-1251","article-title":"Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: a TACL pilot study","volume":"26","author":"Burke","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic Myeloid Leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.bbrc.2023.09.023_bib119","article-title":"Chronic myeloid leukemia: a model disease of the past, present and future","volume":"10","author":"Minciacchi","year":"2021","journal-title":"Cells-Basel"},{"key":"10.1016\/j.bbrc.2023.09.023_bib120","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.09.023_bib121","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbrc.2023.09.023_bib122","article-title":"HDAC1,2 knock-out and HDACi induced cell apoptosis in imatinib-resistant K562 cells","volume":"20","author":"Chen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2023.09.023_bib123","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib124","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","article-title":"The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr\/Abl+ cells sensitive and resistant to STI571","volume":"102","author":"Yu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.09.023_bib125","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","article-title":"Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3","volume":"105","author":"George","year":"2005","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbrc.2023.09.023_bib126","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1007\/s10637-010-9590-4","article-title":"Deactylase inhibition in myeloproliferative neoplasms","volume":"28","author":"Mithraprabhu","year":"2010","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.bbrc.2023.09.023_bib127","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s13577-023-00919-1","article-title":"HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway","volume":"36","author":"Yin","year":"2023","journal-title":"Hum. Cell"},{"key":"10.1016\/j.bbrc.2023.09.023_bib128","article-title":"I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition","volume":"14","author":"Gao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib129","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1158\/1078-0432.CCR-11-0234","article-title":"HDAC inhibitors potentiate the activity of the BCR\/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR\/ABL+ leukemia cells in vitro and in vivo","volume":"17","author":"Nguyen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib130","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.canlet.2014.10.033","article-title":"Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1","volume":"356","author":"Wang","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2023.09.023_bib131","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2023.09.023_bib132","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.7150\/thno.16139","article-title":"Depletion of gamma-catenin by histone deacetylase inhibition confers elimination of CML stem cells in combination with imatinib","volume":"6","author":"Jin","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2023.09.023_bib133","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13148-020-00839-z","article-title":"Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL\/MYC-signaling: effect on imatinib resistance and stem cells","volume":"12","author":"Lernoux","year":"2020","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.bbrc.2023.09.023_bib134","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2023.09.023_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110390","article-title":"A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells","volume":"129","author":"He","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2023.09.023_bib136","first-page":"483","article-title":"HDAC I\/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells","volume":"21","author":"Qiu","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.bbrc.2023.09.023_bib137","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1078-0432.CCR-12-2799","article-title":"PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR\/ABL+ leukemia cells in vitro and in vivo","volume":"19","author":"Dasmahapatra","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib138","article-title":"Novel therapeutic approaches in chronic myeloid leukemia","volume":"91","author":"Ozgur","year":"2020","journal-title":"Leukemia Res"},{"key":"10.1016\/j.bbrc.2023.09.023_bib139","first-page":"128","article-title":"Sequencing of chronic lymphocytic leukemia therapies","volume":"2016","author":"Barrientos","year":"2016","journal-title":"Hematol-Am Soc Hemat"},{"key":"10.1016\/j.bbrc.2023.09.023_bib140","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood-2011-05-351510","article-title":"Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia","volume":"119","author":"Sampath","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.09.023_bib141","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4161\/epi.22674","article-title":"HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance","volume":"7","author":"Van Damme","year":"2012","journal-title":"Epigenetics-US"},{"key":"10.1016\/j.bbrc.2023.09.023_bib142","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1634\/theoncologist.4-5-352","article-title":"Chronic lymphocytic leukemia","volume":"4","author":"Kalil","year":"1999","journal-title":"Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib143","doi-asserted-by":"crossref","first-page":"37409","DOI":"10.18632\/oncotarget.16964","article-title":"The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo","volume":"8","author":"Scialdone","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2023.09.023_bib144","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/1535-7163.MCT-09-1000","article-title":"The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade","volume":"9","author":"El-Khoury","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bbrc.2023.09.023_bib145","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.leu.2403388","article-title":"The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells","volume":"18","author":"Lucas","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2023.09.023_bib146","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2002-12-3794","article-title":"Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein","volume":"102","author":"Aron","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.09.023_bib147","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00432-014-1689-0","article-title":"Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation","volume":"140","author":"Peiffer","year":"2014","journal-title":"J Cancer Res Clin"},{"key":"10.1016\/j.bbrc.2023.09.023_bib148","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/leu.2014.19","article-title":"Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia","volume":"28","author":"El-Khoury","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2023.09.023_bib149","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","article-title":"Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia","volume":"147","author":"Blum","year":"2009","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.bbrc.2023.09.023_bib150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10495-013-0906-7","article-title":"Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells","volume":"19","author":"Yoon","year":"2014","journal-title":"Apoptosis"},{"key":"10.1016\/j.bbrc.2023.09.023_bib151","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-07-1934","article-title":"Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells","volume":"14","author":"Dai","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib152","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1038\/sj.onc.1205853","article-title":"Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia","volume":"21","author":"MacFarlane","year":"2002","journal-title":"Oncogene"},{"issue":"Suppl 2","key":"10.1016\/j.bbrc.2023.09.023_bib153","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1038\/sj.cdd.4401535","article-title":"Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies","volume":"11","author":"Inoue","year":"2004","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbrc.2023.09.023_bib154","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/408038","article-title":"Synergistic induction of apoptosis in primary B-CLL cells after treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand and histone deacetylase inhibitors","volume":"2009","author":"Norian","year":"2009","journal-title":"J Oncol"},{"key":"10.1016\/j.bbrc.2023.09.023_bib155","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","article-title":"A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.09.023_bib156","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10637-015-0206-x","article-title":"Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia","volume":"33","author":"Morschhauser","year":"2015","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.bbrc.2023.09.023_bib157","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1080\/10428194.2016.1276287","article-title":"A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma","volume":"58","author":"Holkova","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2023.09.023_bib158","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib159","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1517\/14728221003796609","article-title":"Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma","volume":"14","author":"Adams","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbrc.2023.09.023_bib160","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.3109\/10428194.2015.1034705","article-title":"Analysis of class I and II histone deacetylase gene expression in human leukemia","volume":"56","author":"Yang","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2023.09.023_bib161","doi-asserted-by":"crossref","first-page":"112152","DOI":"10.18632\/oncotarget.22899","article-title":"MEF2 signaling and human diseases","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2023.09.023_bib162","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2141.2005.05873.x","article-title":"P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors","volume":"132","author":"Brusa","year":"2006","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.bbrc.2023.09.023_bib163","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1541-7786.MCR-16-0242-T","article-title":"EZH2 or HDAC1 inhibition reverses multiple myeloma-induced epigenetic suppression of osteoblast differentiation","volume":"15","author":"Adamik","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib164","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","article-title":"Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma","volume":"9","author":"Mithraprabhu","year":"2014","journal-title":"Epigenetics-US"},{"key":"10.1016\/j.bbrc.2023.09.023_bib165","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.3390\/nu6104273","article-title":"The role of dietary histone deacetylases (HDACs) inhibitors in health and disease","volume":"6","author":"Bassett","year":"2014","journal-title":"Nutrients"},{"key":"10.1016\/j.bbrc.2023.09.023_bib166","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000334577","article-title":"Histone deacetylase in chronic lymphocytic leukemia","volume":"81","author":"Wang","year":"2011","journal-title":"Oncology-Basel"},{"key":"10.1016\/j.bbrc.2023.09.023_bib167","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41375-019-0493-x","article-title":"Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling","volume":"34","author":"Ho","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2023.09.023_bib168","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.stem.2015.08.004","article-title":"HDAC8 inhibition specifically targets inv(16) acute myeloid leukemic stem cells by restoring p53 acetylation","volume":"17","author":"Qi","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbrc.2023.09.023_bib169","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.leukres.2013.07.016","article-title":"The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia","volume":"37","author":"Gruhn","year":"2013","journal-title":"Leukemia Res"},{"key":"10.1016\/j.bbrc.2023.09.023_bib170","doi-asserted-by":"crossref","first-page":"994","DOI":"10.7150\/ijms.8522","article-title":"Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance","volume":"11","author":"Lee","year":"2014","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.bbrc.2023.09.023_bib171","doi-asserted-by":"crossref","first-page":"41966","DOI":"10.1074\/jbc.M406320200","article-title":"Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity","volume":"279","author":"Kato","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2023.09.023_bib172","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10428194.2011.597905","article-title":"Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms","volume":"53","author":"Skov","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2023.09.023_bib173","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1038\/s41388-018-0234-z","article-title":"Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells","volume":"37","author":"Pinazza","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2023.09.023_bib174","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2559.2008.03109.x","article-title":"Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma","volume":"53","author":"Marquard","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.bbrc.2023.09.023_bib175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/epi.14.69","article-title":"Histone deacetylase 6 in health and disease","volume":"7","author":"Seidel","year":"2015","journal-title":"Epigenomics-UK"},{"key":"10.1016\/j.bbrc.2023.09.023_bib176","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2013.03.016","article-title":"Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy","volume":"13","author":"Kaufman","year":"2013","journal-title":"Cl Lymph Myelom Leuk"},{"key":"10.1016\/j.bbrc.2023.09.023_bib177","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1101\/gad.436407","article-title":"HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates","volume":"21","author":"Boyault","year":"2007","journal-title":"Gene Dev."},{"key":"10.1016\/j.bbrc.2023.09.023_bib178","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2010-08-303701","article-title":"HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma","volume":"117","author":"Buglio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.09.023_bib179","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1038\/onc.2011.37","article-title":"SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production","volume":"30","author":"Bell","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2023.09.023_bib180","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.exphem.2019.09.025","article-title":"Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat","volume":"79","author":"McPherson","year":"2019","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib181","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13148-016-0245-y","article-title":"Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients","volume":"8","author":"Pera","year":"2016","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.bbrc.2023.09.023_bib182","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","article-title":"A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia","volume":"81","author":"Gimsing","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib183","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/08880018.2020.1752869","article-title":"A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies","volume":"37","author":"Goldberg","year":"2020","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib184","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2013.38","article-title":"Phase Ia\/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies","volume":"27","author":"DeAngelo","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2023.09.023_bib185","first-page":"47","article-title":"Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents","volume":"7","author":"Ververis","year":"2013","journal-title":"Biol. Targets & Ther."},{"key":"10.1016\/j.bbrc.2023.09.023_bib186","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/10428194.2018.1492122","article-title":"Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study","volume":"60","author":"Walewski","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2023.09.023_bib187","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12885-015-1432-5","volume":"15","author":"Grishina","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2023.09.023_bib188","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/15592294.2016.1187350","article-title":"Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks","volume":"11","author":"Rucker","year":"2016","journal-title":"Epigenetics-US"},{"key":"10.1016\/j.bbrc.2023.09.023_bib189","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2013-12-546283","article-title":"Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients","volume":"123","author":"Tassara","year":"2014","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bbrc.2023.09.023_bib190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00277-005-0026-8","article-title":"Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia","volume":"84","author":"Kuendgen","year":"2005","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib191","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2023.09.023_bib192","first-page":"963","article-title":"Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia","volume":"8","author":"Gore","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.09.023_bib193","first-page":"336","article-title":"Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma","volume":"117","author":"Niesvizky","year":"2011","journal-title":"Cancer-Am Cancer Soc"},{"key":"10.1016\/j.bbrc.2023.09.023_bib194","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/10428194.2018.1515937","article-title":"A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 studydagger","volume":"60","author":"Reiman","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2023.09.023_bib195","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1182\/blood-2011-03-339879","article-title":"A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma","volume":"118","author":"Harrison","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2023.09.023_bib196","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib197","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.leukres.2016.09.003","article-title":"Differentiation therapy in poor risk myeloid malignancies: results of companion phase II studies","volume":"49","author":"Norsworthy","year":"2016","journal-title":"Leukemia Res"},{"key":"10.1016\/j.bbrc.2023.09.023_bib198","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjh.13832","article-title":"Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study","volume":"172","author":"Prebet","year":"2016","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.bbrc.2023.09.023_bib199","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.26499","article-title":"Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: a multicenter phase II trial","volume":"97","author":"Wang","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib200","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2023.09.023_bib201","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/CM9.0000000000002636","article-title":"Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial","volume":"136","author":"Xia","year":"2023","journal-title":"Chinese Med J-Peking"},{"key":"10.1016\/j.bbrc.2023.09.023_bib202","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13148-023-01436-6","article-title":"Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK\/T-cell lymphoma to chidamide","volume":"15","author":"Chen","year":"2023","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.bbrc.2023.09.023_bib203","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/ijc.33761","article-title":"A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed\/refractory non-Hodgkin's lymphomas","volume":"149","author":"Ji","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2023.09.023_bib204","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ijrobp.2022.04.001","article-title":"First-line chemoradiation with or without chidamide (tucidinostat) in patients with intermediate- and high-risk early-stage extranodal nasal-type natural killer\/T-cell lymphoma: a randomized phase 2 study in China","volume":"113","author":"Chai","year":"2022","journal-title":"Int J Radiat Oncol"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23010537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23010537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:32:58Z","timestamp":1757766778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X23010537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":204,"alternative-id":["S0006291X23010537"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.09.023","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDAC inhibitors: Promising agents for leukemia treatment","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}